Key result
Serum NT-proBNP >326 pg/dL linked to ~2.3-fold higher risk of in-hospital stroke complications.
Why the study?
Knowledge regarding the association of NT-proBNP with systemic and neurological in-hospital complications after acute ischemic stroke is scarce.
Are elevated admission serum NT-proBNP levels (>326 pg/dL) associated with an increased risk of in-hospital systemic and neurological complications in patients with acute ischemic stroke?
Cohort (n=308)
Physician in charge and central laboratory technicians were blinded to the objectives/conduct of the study
No
Are elevated admission serum NT-proBNP levels (>326 pg/dL) associated with an increased risk of in-hospital systemic and neurological complications in patients with acute ischemic stroke?
Admission serum NT-proBNP >326 pg/dL independently doubles the odds of developing in-hospital systemic complications in patients hospitalized for acute ischemic stroke.
May support NT-proBNP for identifying systemic complication risk after ischemic stroke; leaves open prospective validation before clinical adoption.
Previous studies have shown the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) with stroke mortality and functional outcome after an acute ischemic stroke (AIS). Knowledge of its association with systemic and neurological in-hospital complications is scarce. Our objective is to analyze this. We performed an observational, retrospective study that included consecutive AIS patients during a 1-year period (2020). A multivariate analysis was performed to identify if NT-proBNP levels were independently associated with in-hospital complications. 308 patients were included, of whom 96 (31.1%) developed systemic and 62 (20.12%) neurological in-hospital complications. Patients with any complication (39.3%) showed higher NT-proBNP levels than those without (median (IQR): 864 (2556) vs. 142 (623) pg/dL, p < 0.001). The receiver operating characteristic curve (ROC) pointed to 326 pg/dL of NT-proBNP as the optimal cutoff level for developing in-hospital systemic complications (63.6% sensitivity and 64.7% specificity for any complication; 66.7% and 62.7% for systemic; and 62.9% and 57.7% for neurological complications). Multivariate analyses showed that NT-proBNP > 326 pg/dL was associated with systemic complications (OR 2.336, 95% CI: 1.259–4.335), adjusted for confounders. This did not reach statistical significance for neurological complications. NT-proBNP could be a predictor of in-hospital systemic complications in AIS patients. Further studies are needed.
No takes yet. Share an insight, caveat, or question.
Ruiz-Franco et al. (2023) conducted a cohort in Acute ischemic stroke (n=308). Elevated serum NT-proBNP levels (>326 pg/dL) vs. Serum NT-proBNP levels <=326 pg/dL was evaluated on In-hospital systemic complications (OR 2.336, 95% CI 1.259–4.335). Serum NT-proBNP >326 pg/dL was independently associated with an increased risk of in-hospital systemic complications after acute ischemic stroke (OR 2.336, 95% CI 1.259–4.335).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: